Intellia Therapeutics Inc (NASDAQ:NTLA) shares, rose in value on Thursday, January 02, with the stock price up by 2.57% to the previous day’s close as strong demand from buyers drove the stock to $11.96.
Actively observing the price movement in the recent trading, the stock is buoying the session at $11.66, falling within a range of $11.7403 and $12.19. The value of beta (5-year monthly) is 1.806. Referring to stock’s 52-week performance, its high was $34.87, and the low was $11.34. On the whole, NTLA has fluctuated by -23.97% over the past month.
With the market capitalization of Intellia Therapeutics Inc currently standing at about $1.22 billion, investors are eagerly awaiting this quarter’s results, scheduled for in February.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 8.9M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that NTLA’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of NTLA currently trading nearly -7.58% and -17.55% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 37.12, while the 7-day volatility ratio is showing 4.47% which for the 30-day chart, stands at 5.74%. Furthermore, Intellia Therapeutics Inc (NTLA)’s beta value is 1.83, and its average true range (ATR) is 0.76.
A comparison of Intellia Therapeutics Inc (NTLA) with its peers suggests the former has fared considerably weaker in the market. NTLA showed an intraday change of 2.57% in today’s session so far, and over the past year, it shrunk by -61.19%%.
Data on historical trading for Intellia Therapeutics Inc (NASDAQ:NTLA) indicates that the trading volumes over the past 10 days have averaged 2.52 and over the past 3 months, they’ve averaged 2.62 million. According to company’s latest data on outstanding shares, there are 101.80 million shares outstanding.
Nearly 1.71% of Intellia Therapeutics Inc’s shares belong to company insiders and institutional investors own 92.38% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 19.81 million shares as on 2024-12-13, resulting in a short ratio of 7.41. According to the data, the short interest in Intellia Therapeutics Inc (NTLA) stood at 2215.00 of shares outstanding as of 2024-12-13; the number of short shares registered in 2024-11-15 reached 16.37 million. The stock has risen by 2.57% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the NTLA stock heading into the next quarter.
